交银国际研究 每日晨报 2025 年 6 月 11 日 今日焦点 交银国际 2025 下半年市场展望 潮涌但见新航路 交银国际研究团队 全球宏观再平衡浪潮奔涌，不确定性与新机遇交织并行。于此变局之中， 中国经济锚定自身航向，在秩序重塑中积蓄坚韧动能。我们坚信，于潮 涌之处，方见新航路之开辟。 请点击以下链接阅读各团队的 2025 下半年展望： 全球宏观 – 再平衡 | 汽车行业月报 5 月新能源车渗透率 | 52.9%，预计 6 月车市增速 | 评级: 领先 | | --- | --- | --- | | 平稳 | | | | 陈庆 | angus.chan@bocomgroup.com | | 5 月全国乘用车市场零售 193.2 万辆，同/环比+13.3%/+10.1%；1-5 月乘 用车零售累计同比+9.1%。自主品牌表现优于行业整体，5 月自主品牌零 售 126 万辆，全国零售份额 65.2%。 此报告最后部分的分析师披露、商业关系披露和免责声明为报告的一部分，必须阅读。 下载本公司之研究报告，可从彭博信息：BOCM 或 https://research.bocomgroup.com | 全球主要指数 ...

Investment Rating - The report assigns a "Leading" investment rating to the automotive industry, indicating an expectation of attractive performance relative to the benchmark index over the next 12 months [5]. Core Insights - In May, the retail sales of passenger vehicles increased by 13.3% year-on-year, driven by consumer promotion policies, increased subsidies from manufacturers, and supportive financial policies. The total retail sales reached 1.932 million units in May, with a year-to-date growth of 9.1% [5]. - The penetration rate of new energy vehicles (NEVs) rose to 52.9% in May, with NEV retail sales reaching 1.021 million units, reflecting a year-on-year increase of 28.2% [5]. - The export structure is improving, with the EU and Southeast Asia emerging as new high-growth markets. In May, total passenger vehicle exports reached 448,000 units, with NEV exports performing better than traditional fuel vehicles [5]. Summary by Sections Valuation Overview - BYD Co., Ltd. (1211 HK) rated "Buy" with a target price of 503.25, current price 396.60, FY25E EPS of 23.284, and a PE ratio of 15.6 [3]. - Great Wall Motors (2333 HK) rated "Buy" with a target price of 17.36, current price 12.58, FY25E EPS of 1.692, and a PE ratio of 6.8 [3]. - Geely Automobile (175 HK) rated "Buy" with a target price of 22.50, current price 17.56, FY25E EPS of 1.182, and a PE ratio of 13.6 [3]. - Xpeng Motors (9868 HK) rated "Buy" with a target price of 134.69, current price 78.55, FY25E EPS of -0.324, and NA for PE ratio [3]. - NIO Inc. (9866 HK) rated "Buy" with a target price of 48.96, current price 27.90, FY25E EPS of -7.459, and NA for PE ratio [3]. Market Trends - The report notes that the automotive market is expected to maintain stable growth in June, following a strong performance in May. The report highlights the potential for a price war among passenger vehicles, particularly after BYD initiated a new round of promotions [5]. - The report emphasizes the strong performance of domestic brands, which accounted for 65.2% of the retail market share in May, with a year-on-year increase of 8 percentage points [5]. Investment Recommendations - The report suggests focusing on BYD for its intelligent driving and export potential, Xpeng Motors for the launch of new models, and Geely Automobile for internal resource integration following the privatization of its Zeekr brand [5].

交银国际研究 每日晨报 2025 年 6 月 10 日 今日焦点 | 全球宏观 | | | --- | --- | | 从日债到美债：全球期限溢价的涟漪 | 宏观策略 | | 李少金 Evan.Li@bocomgroup.com | | 作为全球第二大债券市场，日本超长债收益率的快速上涨，折射出全球 债券市场在财政扩张与央行政策分化背景下的结构性变化。在关税贸易 政策不确定性持续的当下，市场对各国财政政策进一步宽松的预期正推 高风险溢价，或预示着全球长端利率重估周期的来临。 | 全球主要指数 | | | | | --- | --- | --- | --- | | | | | 年初至今 | | | 收盘价 | 升跌% | 升跌% | | 恒指 | 24,181 | 1.61 | 17.43 | | 国指 | 8,780 | 1.74 | 20.44 | | 上 A | 3,563 | 0.43 | 1.42 | | 上 B | 257 | 0.26 | -3.92 | | 深 A | 2,120 | 0.93 | 3.53 | | 深 B | 1,188 | -0.49 | -2.07 | | 道指 | 42, ...

Global Macro - The rapid rise in Japanese super-long government bond yields since mid-May 2025 has triggered turbulence in the global bond market, with the 40-year bond yield surpassing 3.68%, the highest since its issuance in 2007 [2][6][23] - The increase in yields reflects structural changes in the global bond market amid fiscal expansion and diverging central bank policies, with expectations of further fiscal easing pushing up risk premiums [2][6][23] Japanese Long-term Bond Yield Dynamics - The primary driver of the recent rise in Japanese long-term bond yields is the gradual normalization of the Bank of Japan's monetary policy, which has created conditions for the repricing of super-long government bonds [3][24] - A structural imbalance in supply and demand has exacerbated market volatility, as the absence of the Bank of Japan as a "super buyer" has removed crucial market support [3][30] - The demand side is also under pressure, with rising interest rate expectations leading domestic institutional investors to adopt a wait-and-see approach, further weakening buying power [3][37] Economic Challenges and Policy Dilemmas - Japan's economy faces dual challenges of weak domestic demand and external tariff shocks, with the central bank caught in a policy dilemma [3][52] - The government debt-to-GDP ratio has surpassed 260%, raising concerns about fiscal sustainability as rising long-term bond yields increase borrowing costs [3][60] Spillover Effects on Global Bond Markets - The volatility in Japanese long-term bond yields has significant spillover effects on the U.S. Treasury market, with Japanese insurers and pension funds potentially exerting structural selling pressure on U.S. bonds [3][64] - The global bond market is undergoing a systematic reassessment of risk premiums, with Japan's long-term bond yields acting as a "ballast" in the global interest rate system [3][70] U.S. Treasury Yield Outlook - Short-term risks for U.S. Treasury yields are notable, with expectations of a resolution to the debt ceiling issue leading to substantial net issuance of $300-400 billion within 2-3 months [3][91] - The anticipated fiscal policies under the Trump administration may further pressure U.S. Treasury yields, with a projected range of 4.0-5.0% for the 10-year yield by the end of 2025 [3][105]

New Energy Industry - The report highlights that despite uncertainties, opportunities still exist in the new energy sector, particularly focusing on dividend stability [1] - The preferred investment order is operators > photovoltaic glass > polysilicon > inverters > battery cells, with China Power (2380 HK) and Jingneng Clean Energy (579 HK) being top picks [1] - The photovoltaic sector is expected to see significant earnings improvement in Q1 2025, with Fuyat (6865 HK) and GCL-Poly Energy (3800 HK) also recommended for investment [1] Wind Power - The report anticipates a 23% year-on-year increase in new wind power installations in 2025, although adjustments may occur post-installation [2] - A conservative estimate suggests a slight decline in new installations in 2026, contingent on new policy impacts and project pricing [2] Zhiwen Group - The company is projected to experience a revenue turning point in the second half of 2025, driven by accelerated overseas growth [3] - Revenue and adjusted net profit forecasts for 2025 have been raised by 5% and 13% respectively, with a target price increase to $8.30 [3][4] - The first quarter of 2025 showed a revenue of 2.52 billion yuan, exceeding market expectations by 4%, primarily due to a 72% year-on-year growth in overseas business [3] IBI363 by Innovent Biologics - Early clinical data for IBI363 in treating I/O resistant NSCLC shows promising results, with an overall response rate (ORR) of 26-37% and median progression-free survival (PFS) of 5.5-9.3 months [7][8] - The potential market for IBI363 is significant, especially given the limited effective therapies available for post-PD-(L)1 treatment [8] - The target price for IBI363 has been raised to 84 HKD, reflecting its strong market potential [8] Economic Data - Upcoming economic data releases include the Consumer Price Index and unemployment claims in the US, with expectations set for various metrics [9]

Investment Rating - The report assigns a "Buy" rating to multiple companies in the renewable energy sector, including China Power (2380 HK), China Resources Power (836 HK), and GCL-Poly Energy (3800 HK) [2][4]. Core Insights - The renewable energy operators face both challenges and opportunities under new policies, with dividend levels showing relative certainty. The introduction of Document No. 136 in 2025 is expected to shift the long-term strategies of operators significantly [1][7]. - The solar photovoltaic (PV) industry is anticipated to experience a substantial capacity clearance, with stock prices declining, presenting opportunities for leading companies. The demand for solar PV is expected to remain strong in 2024, but a short-term adjustment in demand is likely following the end of the rush to install projects [17][20]. - Wind power installations are projected to grow by 23% in 2025, reaching 98 GW, but a slight decline is expected in 2026 due to adjustments in pricing mechanisms [4][6]. Summary by Sections Operators - Operators are expected to focus on maintaining dividend rates, with an average dividend yield of around 6% across the covered companies. The report highlights that operators with strong technical capabilities and scale advantages will be better positioned to adapt to market changes [11][14]. - The new pricing mechanism will require operators to optimize project management and respond to fluctuations in electricity prices [7][8]. Photovoltaic Industry - The report predicts that the global demand for solar PV will slow down in 2025, with a projected installation of approximately 270 GW in China, a 3% decrease year-on-year [22]. - The solar glass sector is expected to see a rebound in prices after a strong recovery, but future supply may decrease due to regulatory requirements for capacity replacement [37][38]. Wind Power - The report anticipates that the wind power sector will see a significant increase in new installations in 2025, but a potential decline in 2026 due to the new pricing mechanism and market adjustments [4][6]. - The profitability of wind turbine manufacturers will depend on their ability to deliver projects in offshore and international markets [4][6]. Financial Metrics - The report provides detailed financial metrics for various companies, including earnings per share, price-to-earnings ratios, and dividend yields, indicating a generally favorable outlook for operators in the renewable energy sector [2][4][14].

Investment Rating - The report upgrades the investment rating of the company to "Buy" based on better-than-expected overseas business growth and effective marketing cost control [2]. Core Insights - The company is expected to see a revenue inflection point in the second half of the year, driven by accelerated overseas growth, leading to a 5% increase in the 2025 revenue forecast and a 13% increase in adjusted net profit forecast to 1.4 billion RMB [2]. - The target price has been raised to $8.30 from $7.20, reflecting a potential upside of 17.6% [1][2]. - The company's market capitalization is approximately $1.2 billion, which is below its net cash of $1.4 billion as of Q1 2024, indicating limited downside risk for the stock price [2]. Financial Performance Summary - For Q1 2025, the company reported revenues of 2.52 billion RMB, a slight year-over-year decline of 2%, but exceeding market expectations by 4% [6]. - The adjusted net profit for Q1 2025 was 400 million RMB, significantly better than the market expectation of 270 million RMB, aided by channel optimization and improved marketing efficiency [6]. - The overseas revenue grew by 72% year-over-year, contributing to 16% of total revenue, driven by the rapid growth of new products [6][12]. Revenue and Profit Forecasts - The updated revenue forecasts for 2025, 2026, and 2027 are 10.485 billion RMB, 10.724 billion RMB, and 11.090 billion RMB, respectively, reflecting a growth of 5% and 6% compared to previous estimates [5][20]. - The adjusted net profit forecasts for the same years are 1.404 billion RMB, 1.427 billion RMB, and 1.456 billion RMB, indicating a steady growth trajectory [5][20]. Market Position and Valuation - The company’s stock price has shown a year-to-date decline of 8.43%, with a 52-week high of $8.15 and a low of $5.27 [4]. - The report highlights that the company maintains a stable shareholder return policy, further supporting its valuation [2].

Investment Rating - The report maintains a "Buy" rating for the company, Sihuan Pharmaceutical (02096), with a target price of HKD 14.3, and continues to recommend it as a key focus in the industry [1]. Core Insights - The report has raised the profit forecast for the company for the years 2025-2027 by 6-11% and is optimistic about the potential for more overseas transactions in the short term, particularly focusing on targets such as CDH6 and CDH17, which have recently garnered significant attention [1]. - At the ASCO 2025 conference, the company's oncology pipeline showcased 18 research studies. Key studies to watch include: 1. The final analysis of overall survival (OS) in a Phase III study of Suviscita monoclonal antibody for platinum-resistant ovarian cancer, with median OS of 15.3 months for the treatment group compared to 14 months for the control group, with approval expected within the year [1]. 2. The results of an Ib phase study on SIM0270 combined with Palbociclib for second-line or higher ER+/HER2- breast cancer, showing an overall response rate (ORR) of 41.5% and clinical benefit rate (CBR) of 82.5%, with rates of 87.5% and 100% respectively in baseline ESR1 mutation patients. The company is currently conducting a Phase III study to evaluate the efficacy of SIM0270 combined with Everolimus in CDK4/6 inhibitor-treated ER+/HER2- breast cancer [1].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 84.00, indicating a potential upside of 16.2% from the current price of HKD 72.30 [4][14]. Core Insights - The early data for IBI363 in lung cancer is encouraging, revealing a significant market opportunity. The target price has been raised due to the inclusion of IBI363 in the valuation model, with an estimated peak sales potential of approximately USD 1.5 billion by 2028 [2][7]. - The company plans to initiate a Phase III registration study for IBI363 in squamous NSCLC patients who have failed prior PD-(L)1 therapy, having received breakthrough therapy designation from CDE [7][10]. Financial Overview - Revenue projections show a strong growth trajectory, with expected revenues of RMB 6,206 million in 2023, increasing to RMB 17,071 million by 2027, representing a compound annual growth rate (CAGR) of 36.2% from 2023 to 2024 and 20.0% from 2026 to 2027 [3][15]. - The net profit is projected to turn positive in 2025, with an estimated net profit of RMB 751 million, growing to RMB 3,242 million by 2027 [3][15]. - The earnings per share (EPS) is expected to improve significantly, moving from a loss of RMB 0.66 in 2023 to a profit of RMB 1.97 by 2027 [3][15]. Clinical Data Highlights - IBI363 demonstrated an overall response rate (ORR) of 26-37% in squamous NSCLC patients, with a median progression-free survival (PFS) of 5.5-9.3 months and a median overall survival (OS) exceeding 15.3 months [7][8]. - In the non-squamous NSCLC cohort, the ORR was 24% with a median PFS of 5.6 months, indicating the drug's potential effectiveness in a challenging treatment landscape [7][9]. Market Potential - The report highlights a significant unmet need in the second-line treatment for I/O resistant NSCLC patients, with current therapies showing an ORR of less than 20% and median PFS/OS of less than 4 months/12 months [7][10]. - The global sales for PD-(L)1 drugs are projected to exceed USD 40 billion in 2024, underscoring the substantial market opportunity for effective therapies like IBI363 [7].

Industry Rating - The report rates the internet industry as "Leading" [1] Core Insights - The report highlights that Tencent's domestic revenue increased by 800 million CNY (4%) year-on-year, primarily driven by "Honor of Kings" and new game releases [1] - NetEase's mobile game revenue showed a slight decline of 100 million CNY (2%) year-on-year, but new game contributions offset the impact of high base effects [1] - The overall performance of top mobile games remained stable, with a year-on-year increase of 6% from January to May 2025, aligning with expectations [4][6] Summary by Sections Investment Rating - Tencent and NetEase are both rated as "Buy" with respective price-to-earnings ratios of 17.2 and 15.6 for 2025 [5][41] Revenue Performance - Tencent's domestic mobile game revenue reached a new high of nearly 5 billion CNY in May, with "Delta Action" contributing significantly [1][14] - NetEase's "Yanyun Sixteen Sounds" achieved a record high revenue close to 300 million CNY in May [17] New Game Releases - Tencent and NetEase are set to release multiple new games in June, including "Final Fantasy 14: Crystal World" and "Marvel Secret War" [5][32] Market Trends - The report notes that Tencent's overseas revenue decreased by 860 million CNY (15%) year-on-year, primarily due to high base effects from "Brawl Stars" [21] - In contrast, NetEase's overseas revenue increased by 150 million CNY (29%), benefiting from contributions from "Peak Speed" and new releases [21] Valuation Overview - The report provides a valuation summary for key gaming companies, indicating Tencent's market capitalization at approximately 599.6 billion CNY and NetEase at around 79.8 billion CNY [41]